New therapeutic strategy for refractory ovarian carcinoma based on function of Glypican-3

我们以前报道过，磷脂酰肌醇蛋白聚糖-3，硫酸乙酰肝素蛋白聚糖，在卵巢透明细胞癌中过表达。我们评估磷脂酰肌醇蛋白聚糖-3在卵巢透明细胞癌中的功能。我们发现Glypican-3通过PI 3 K/AKT轴以IGF-II依赖的方式与细胞生长抑制相关，Glypican-3表达与早期卵巢透明细胞癌患者的短无进展生存期相关。我们评估了抗磷脂酰肌醇蛋白聚糖-3抗体的细胞毒性。尽管抗Glypican-3抗体的细胞毒性在体外得到证实，但紫杉醇和抗Glypican-3抗体在体内联合治疗不再观察到生存时间。

We previously reported that Glypican-3, a heparan sulfate proteoglycan, was overexpressed in clear cell carcinoma of ovary. We evaluated function of Glypican-3 in clear cell carcinoma of ovary. We showed that Glypican-3 was associated with cell growth inhibition in IGF-II dependent way through PI3K/AKT axis.Glypican-3 expression was associated with short progression-free survival in early stage clear cell carcinoma of ovary patients. We evaluated cytotoxicity of the anti-Glypican-3 antibody. Although cytotoxicity of the anti Glypican-3 antibody was confirmed in vitro, no longer survival time was seen by combination therapy of paclitaxel and anti Glypican-3 antibody in vivo.